Aligos Therapeutics (ALGS) Cash from Investing Activities (2019 - 2026)

Aligos Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at $34.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 179.27% year-over-year to $34.9 million; the trailing twelve-month figure through Mar 2026 stood at $41.2 million (up 56.57% YoY), and the FY2025 full-year result was -$37.8 million, down 106.94% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $34.9 million, up from -$2.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $47.7 million in Q3 2025, with the low at -$88.6 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$146235.3 across 5 years, with a median of $10.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 723.17% — and 2024, when it jumped 285414.29%.
• Aligos Therapeutics' Cash from Investing Activities stood at $11.6 million in 2022, then sank by 100.06% to -$7000.0 in 2023, then jumped by 285414.29% to $20.0 million in 2024, then tumbled by 110.12% to -$2.0 million in 2025, then soared by 1828.4% to $34.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $34.9 million (Q1 2026), -$2.0 million (Q4 2025), and $47.7 million (Q3 2025), per Business Quant data.